CreaGen Cost-Effective Medicinal Chemistry Research Services
CreaGen’s cost effective-medicinal chemistry program is an attractive program for virtual, start-up, biotechnology, all sizes of pharmaceutical companies as well as start-up companies. For virtual, start-up and biotechnology companies this program provides the opportunity to eliminate the early investment in medicinal chemistry infrastructure. For pharmaceutical companies, this program serves as an extension of their internal capabilities.
Through this business model CreaGen has successfully implemented medicinal chemistry programs with several biotechnology and pharmaceutical companies in the greater Boston area and beyond, and has delivered excellent results to all its partners.

The model involves
1) Face-to-face meeting with the CreaGen team to discuss the discovery needs of our partner.
2) Taking complete responsibility for the medicinal chemistry program.
3) Identification of an experienced Project Manager from CreaGen.
4) Immediate assignment of a highly qualified and experienced team of PhD scientists to launch and execute the program.
5) Fast turnover of projects with aggressive timelines.
6) Integrated teamwork to produce the customer target molecules.
7) Maintenance of excellent communication during the entire collaborative process.
8) Accurate and confidential record keeping.

Selected achievements through this program

• Taking AMPK target knowledge (no crystal structure), implementing four FTE medicinal chemistry programs and generating an orally bioavailable developmental candidate through scaffold morphing, lead generation and lead optimization iterations in nine months. Participated in due diligence by potential investors. IP was generated.
• Taking a 10 micromolar anti-infective lead compound to a sub-nanomolar advanced lead candidate in six months. IP was generated.
• Designing 100-membered optimized libraries and delivering two micromlar lead compounds.

  CreaGen Inc. makes into the 2018 list of major players in CRO industry   more...
    7th Advances In Chemical Sciences Symposium: May 4th, 2018
The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception   more...
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.